Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

2023496 citationsJournal Articlebronze Open Access

Authors

Lipika Goyal · Harvard University

Funda Meric‐Bernstam · The University of Texas MD Anderson Cancer Center

Antoine Hollebecque · Institut Gustave Roussy

Juan W. Valle · University of Manchester

Chigusa Morizane · Dana-Farber Cancer Institute

Thomas B. Karasic · Hospital of the University of Pennsylvania

Thomas A. Abrams

Abstract

In previously treated patients with <i>FGFR2</i> fusion or rearrangement-positive intrahepatic cholangiocarcinoma, the use of futibatinib, a covalent FGFR inhibitor, led to measurable clinical benefit. (Funded by Taiho Oncology and Taiho Pharmaceutical; FOENIX-CCA2 ClinicalTrials.gov number, NCT02052778.).

Topics & Keywords

Cholangiocarcinoma and Gallbladder Cancer Studies Fibroblast Growth Factor Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 3, pp. 228-239

DOI: 10.1056/nejmoa2206834

Field-Weighted Citation Impact: 156.42